Abstract
A series of N-aryl pyridinone inhibitors of p38 mitogen activated protein (MAP) kinase were designed and prepared based on the screening hit SC-25028 (1) and structural comparisons to VX-745 (5). The focus of the investigation targeted the dependence of potency and metabolic stability on the benzyloxy connectivity, the role of the C-6 position and the substitution pattern on the N-phenyl ring. Further optimization produced the highly selective and potent pyridinones 2 and 3. These inhibitors exhibited activity in both acute and chronic models of inflammation.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Disease Models, Animal
-
Drug Design*
-
Enzyme Activation / drug effects
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Inhibitory Concentration 50
-
Male
-
Microsomes, Liver / enzymology
-
Molecular Structure
-
Pyridazines / chemistry
-
Pyridazines / pharmacology
-
Pyridones / chemical synthesis*
-
Pyridones / chemistry
-
Pyridones / pharmacology*
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors*
Substances
-
Enzyme Inhibitors
-
Pyridazines
-
Pyridones
-
Pyrimidines
-
p38 Mitogen-Activated Protein Kinases
-
VX-745